Novel treatment approaches and pediatric research networks in status epilepticus

Epilepsy Behav. 2019 Dec;101(Pt B):106564. doi: 10.1016/j.yebeh.2019.106564. Epub 2019 Nov 8.

Abstract

This paper contains five contributions which were presented as part of the novel therapies section of the 7th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures. These illustrate recent advances being made in the management and therapy of status epilepticus. The five contributions concern: genetic variations in Na + channel genes and their importance in status epilepticus; the European Reference Network for rare and complex epilepsies EpiCARE; the North American Pediatric Status Epilepticus Research Group (pSERG); Fenfluramine as a potential therapy for status epilepticus' and the valproate derivatives, valnoctamide and sec-butylpropylacetamide (SPD), as potential therapies for status epilepticus. This article is part of the Special Issue "Proceedings of the 7th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures".

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anticonvulsants / therapeutic use*
  • Child
  • Humans
  • Pediatrics / methods*
  • Research*
  • Sodium Channels / genetics
  • Sodium Channels / metabolism
  • Status Epilepticus / drug therapy
  • Status Epilepticus / genetics
  • Status Epilepticus / therapy*

Substances

  • Anticonvulsants
  • Sodium Channels